These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25523657)

  • 21. The Kallikrein Panel for prostate cancer screening: its economic impact.
    Voigt JD; Zappala SM; Vaughan ED; Wein AJ
    Prostate; 2014 Feb; 74(3):250-9. PubMed ID: 24166488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.
    Vickers A; Vertosick EA; Sjoberg DD; Hamdy F; Neal D; Bjartell A; Hugosson J; Donovan JL; Villers A; Zappala S; Lilja H
    J Urol; 2018 Jun; 199(6):1470-1474. PubMed ID: 29366640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years.
    Vertosick EA; Häggström C; Sjoberg DD; Hallmans G; Johansson R; Vickers AJ; Stattin P; Lilja H
    J Urol; 2020 Aug; 204(2):281-288. PubMed ID: 32125228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re: Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
    Noordzij MA; Blanker MH
    J Natl Cancer Inst; 2015 Jun; 107(6):djv110. PubMed ID: 25888716
    [No Abstract]   [Full Text] [Related]  

  • 25. Re: Cost-Effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data.
    Taneja SS
    J Urol; 2015 Jul; 194(1):113-4. PubMed ID: 26088223
    [No Abstract]   [Full Text] [Related]  

  • 26. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
    Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should we screen for prostate cancer? A re-examination of the evidence.
    Del Mar CB; Glasziou PP; Hirst GH; Wright RG; Hoffmann TC
    Med J Aust; 2013 Jun; 198(10):525-7. PubMed ID: 23725255
    [No Abstract]   [Full Text] [Related]  

  • 28. Emerging biomarkers for the diagnosis and prognosis of prostate cancer.
    Sardana G; Dowell B; Diamandis EP
    Clin Chem; 2008 Dec; 54(12):1951-60. PubMed ID: 18927246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging biomarkers in the detection and prognosis of prostate cancer.
    Filella X; Foj L
    Clin Chem Lab Med; 2015 Jun; 53(7):963-73. PubMed ID: 25581761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
    Ulmert D; O'Brien MF; Bjartell AS; Lilja H
    Nat Rev Urol; 2009 Jul; 6(7):384-91. PubMed ID: 19578355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer risk calculators using ERSPC-derived data underestimate the risk if the WHO IRP 96/670 standard is used in prostate-specific antigen analysis.
    Tormey WP
    Eur Urol; 2015 Sep; 68(3):541-2. PubMed ID: 25819721
    [No Abstract]   [Full Text] [Related]  

  • 32. Re: Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?
    Taneja SS
    J Urol; 2015 Jul; 194(1):115. PubMed ID: 26088225
    [No Abstract]   [Full Text] [Related]  

  • 33. Managing localized prostate cancer in the era of prostate-specific antigen screening.
    Brooks JD
    Cancer; 2013 Nov; 119(22):3906-9. PubMed ID: 24006273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
    Kovács GL
    Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
    Bangma CH; van Schaik RH; Blijenberg BG; Roobol MJ; Lilja H; Stenman UH
    Eur J Cancer; 2010 Nov; 46(17):3109-19. PubMed ID: 21047594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current biomarkers for diagnosing of prostate cancer.
    Stephan C; Jung K; Ralla B
    Future Oncol; 2015; 11(20):2743-55. PubMed ID: 26358139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The dilemmas of prostate cancer screening.
    Hugosson J; Carlsson SV
    Med J Aust; 2013 Jun; 198(10):528-9. PubMed ID: 23725256
    [No Abstract]   [Full Text] [Related]  

  • 38. Will emerging prostate cancer markers redeem themselves?
    Hotakainen K; Stenman UH
    Clin Chem; 2010 Aug; 56(8):1212-3. PubMed ID: 20570933
    [No Abstract]   [Full Text] [Related]  

  • 39. [The level of evidence for the use of biomarkers in the early detection of prostate cancer].
    Lamy PJ; Gauchez AS; Salomon L; Haugh M; Ceraline J; Fulla Y; Georges A; Larré S; Loric S; Luporsi E; Martin PM; Mazerolles C; Molinié V; Mongiat-Artus P; Piffret J; Thuillier F; Perrin P; Rebillard X;
    Ann Biol Clin (Paris); 2016; 74(2):227-32. PubMed ID: 27029727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate cancer screening can save lives but it is too early for a national programme, study finds.
    Sayburn A
    BMJ; 2014 Aug; 349():g5055. PubMed ID: 25102993
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.